RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea

        Hui Xing Tan,Desmond Chun Hwee Teo,이동윤,김청수,Jing Wei Neo,Cynthia Sung,Haroun Chahed,Pei San Ang,Doreen Su Yin Tan,박래웅,Sreemanee Raaj Dorajoo 대한의료정보학회 2022 Healthcare Informatics Research Vol.28 No.2

        Objectives: The aim of this study was to characterize the benefits of converting Electronic Medical Records (EMRs) to acommon data model (CDM) and to assess the potential of CDM-converted data to rapidly generate insights for benefitriskassessments in post-market regulatory evaluation and decisions. Methods: EMRs from January 2013 to December 2016were mapped onto the Observational Medical Outcomes Partnership-CDM (OMOP-CDM) schema. Vocabulary mappingswere applied to convert source data values into OMOP-CDM-endorsed terminologies. Existing analytic codes used in a priorOMOP-CDM drug utilization study were modified to conduct an illustrative analysis of oral anticoagulants used for atrialfibrillation in Singapore and South Korea, resembling a typical benefit-risk assessment. A novel visualization is proposed torepresent the comparative effectiveness, safety and utilization of the drugs. Results: Over 90% of records were mapped ontothe OMOP-CDM. The CDM data structures and analytic code templates simplified the querying of data for the analysis. Intotal, 2,419 patients from Singapore and South Korea fulfilled the study criteria, the majority of whom were warfarin users. After 3 months of follow-up, differences in cumulative incidence of bleeding and thromboembolic events were observable viathe proposed visualization, surfacing insights as to the agent of preference in a given clinical setting, which may meaningfullyinform regulatory decision-making. Conclusions: While the structure of the OMOP-CDM and its accessory tools facilitatereal-world data analysis, extending them to fulfil regulatory analytic purposes in the post-market setting, such as benefit-riskassessments, may require layering on additional analytic tools and visualization techniques.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼